non-HDL cholesterol in serum
Jump to navigation
Jump to search
Introduction
Total Cholesterol - HDL-cholesterol
Reference interval
- in statin-treated patients, target non-HDL cholesterol of < 120 mg/dL[4]
Clinical significance
- see lipid panel
- risk of major cardiovascular events associated with increased non-HDL cholesterol > with LDL cholesterol &/or serum apolipoprotein B[2]
- high serum non-HDL cholesterol associated with risk for 1st cardiovascular event
- treating high levels early in life can reduce risk[3]
More general terms
Additional terms
References
- ↑ Journal Watch 24(19):152, 2004 Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15358046
- ↑ 2.0 2.1 Boekholdt SM et al Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins JAMA. 2012;307(12):1302-1309 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22453571 <Internet> http://jama.ama-assn.org/content/307/12/1302.short
- ↑ 3.0 3.1 Brunner FJ et al Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. Dec 3, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31810609 Free Article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32519-X/fulltext
Robinson JG The next treatment paradigm in cardiovascular prevention? Lancet. Dec 3, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31810608 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32949-6/fulltext - ↑ 4.0 4.1 Wendling P ApoB May Better Predict Mortality Risk in Statin-Treated Patients. Medscape - Mar 17, 2021. https://www.medscape.com/viewarticle/947631
Lindhardt Johannesen CD, Mortensen MB, Langsted A, Nordestgaard BG, Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol 2021. 77(11):1439-1450 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33736827 https://www.jacc.org/doi/10.1016/j.jacc.2021.01.027
Stone NJ, Lloyd-Jones D Tracking Residual Risk: Time for a Change? J Am Coll Cardiol 2021. 77(11):1451-1453 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33736828 https://www.jacc.org/doi/10.1016/j.jacc.2021.01.035